* Eledon Pharmaceuticals Inc is expected to show no change in quarterly revenue when it reports results on May 9 (estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Eledon Pharmaceuticals Inc is for a loss of 39 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $10.00, above its last closing price of $2.44.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.39 -0.29 Beat 26
Jan. 1 2023 -0.50 -0.46 -0.35 Beat 24
Jun. 30 2023 -0.46 -0.46 -0.40 Beat 12.8
Mar. 31 2023 -0.58 -0.60 -0.75 Missed -25.2
Dec. -0.78 -0.70 -0.69 Beat 1.6
31 2022
Sep. 30 2022 -0.68 -0.68 -0.73 Missed -7.4
Jun. 30 2022 -0.70 -0.70 -0.65 Beat 7.7
Mar. 31 2022 -0.67 -0.68 -0.69 Missed -1.8
This summary was machine generated May 7 at 11:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments